Aligos Therapeutics (ALGS) Amortizatization of Intangibles (2019 - 2026)
Aligos Therapeutics (ALGS) reported Amortizatization of Intangibles of $419000.0 for Q1 2026, up 32.59% on a YoY basis from $316000.0 in Q1 2025, and down 47.95% quarter-over-quarter from $805000.0 in Q4 2025.
Aligos Therapeutics (ALGS) Amortizatization of Intangibles (2019 - 2026) Analysis & Trends
Aligos Therapeutics has reported Amortizatization of Intangibles for 8 years, with the latest figure at $419000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortizatization of Intangibles rose 32.59% year-over-year to $419000.0; the trailing twelve-month figure through Mar 2026 stood at $2.3 million (up 34.21% YoY), and the FY2025 full-year result was $2.2 million, up 22.71% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $419000.0, down from $805000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $805000.0 in Q4 2025, with the low at -$705000.0 in Q4 2023.
- Historically, Amortizatization of Intangibles has averaged $292529.4 across 5 years, with a median of $354000.0 in 2024.
- The largest YoY upside for Amortizatization of Intangibles was 4433.33% in 2023 against a maximum downside of 1040.0% in 2023.
- Aligos Therapeutics' Amortizatization of Intangibles stood at $75000.0 in 2022, then plunged by 1040.0% to -$705000.0 in 2023, then surged by 187.66% to $618000.0 in 2024, then jumped by 30.26% to $805000.0 in 2025, then slumped by 47.95% to $419000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $419000.0 (Q1 2026), $805000.0 (Q4 2025), and $349000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Aligos Therapeutics | 53.47 Mn | -26.36 Mn | - | 419,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 419,000.00 |
| Mar 31, 2026 | 419,000.00 |
| Dec 31, 2025 | 805,000.00 |
| Dec 31, 2025 | 805,000.00 |
| Sep 30, 2025 | 349,000.00 |
| Sep 30, 2025 | 349,000.00 |
| Jun 30, 2025 | 718,000.00 |
| Jun 30, 2025 | 718,000.00 |
| Mar 31, 2025 | 316,000.00 |
| Mar 31, 2025 | 316,000.00 |
| Dec 31, 2024 | 618,000.00 |
| Dec 31, 2024 | 618,000.00 |
| Sep 30, 2024 | 419,000.00 |
| Sep 30, 2024 | 419,000.00 |
| Jun 30, 2024 | 354,000.00 |
| Jun 30, 2024 | 354,000.00 |
| Mar 31, 2024 | 392,000.00 |
| Mar 31, 2024 | 392,000.00 |
| Dec 31, 2023 | -705,000.00 |
| Dec 31, 2023 | -705,000.00 |